RCS - Verici Dx PLC - Completion of CAP accreditation audit

Verici DxAnnouncement

12/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251112:nRSL1171Ha&default-theme=true

RNS Number : 1171H  Verici Dx PLC  12 November 2025

 

Verici Dx plc

("Verici Dx" or the "Company")

 

Completion of CAP accreditation audit

 

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that it has successfully completed its second
biennial inspection of the Company's clinical laboratory, accredited by the
College of American Pathologists ("CAP"). CAP is one of the leading US
organisations for reviewing clinical laboratories and maintaining this
accreditation is an essential part in continuing to implement the highest
standards in clinical laboratory practice.

 

The inspection passed with no deficiencies, showing Verici Dx's commitment to
compliance and maintaining excellence in daily clinical laboratory operations
according to CAP requirements and their respective annual updates. By
continuing to follow these strict CAP guidelines and pass CAP accreditation
audits, Verici Dx can consistently provide reliable test results under its
quality management system and further improve patient health.

 

Dave Schultenover, VP Quality and Regulatory Affairs at Verici Dx, said:
"Verici Dx values the clinicians and patients that put their trust in our
clinical laboratory, enabling a level of personalised care that has not been
available to kidney transplant patients until now. We are dedicated to
continuing to meet or exceed the regulatory requirements to be a trusted
partner to clinicians."

 

 Verici Dx plc                                 www.vericidx.com (https://vericidx.com/)

 Sara Barrington, CEO                          Via Walbrook PR

 Singer Capital Markets (Nominated adviser, Joint Broker)                     Tel: +44 (0)20 7496 3000
 Phil Davies / Sam Butcher

 Oberon Capital (Joint Broker)                 Tel: +44 (0)20 3179 0500
 Mike Seabrook / Adam Pollock

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
                                               (mailto:vericidx@walbrookpr.com)
 Alice Woodings / Paul McManus                 Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABBBATMTTBBLA



            Copyright 2019 Regulatory News Service, all rights reserved